Literature DB >> 33839579

Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: In vitro, in vivo, and in silico integrated approaches.

Ahmed T A Boraei1, Elsayed H Eltamany2, Ibrahim A I Ali2, Sara M Gebriel2, Mohamed S Nafie3.   

Abstract

Liver cancer is the most common type of cancer in many countries. New studies and statistics show rising liver cancer worldwide, so it is essential to seek new agents for this type of cancer. PIM1 has an attractive target in the discovery of cancer medications as it is very much expressed in a variety of malignancies and influences such as tumorigenesis, cell cycle progression, cellular proliferation, apoptosis, and cell migration. Accordingly, a series of pyridones and pyridine-amides were synthesized and tested for anti-liver cancer activity. In the synthetic strategy 4,6-diaryl-3-cyano-2-pyridones 3a-n were synthesized using one-pot four component synthetic method. Structural modifications were done on 4,6-diphenyl-3-cayno-2-pyridone 3a to enhance the activity. Alkylation in the presence of K2CO3 afforded the O-alkylated products 4-6. The acetoxy hydrazide 7 was synthesized and cyclized into 1,3,4-oxadiazolethione 8 which alkylated on sulfur to give 10. Azide-coupling method was used to couple the 2-(pyridin-2-yloxy)acetohydrazide 7 to different amines and amino acid esters to furnish the products 12a-e and 13a-b. The synthesized derivatives were subjected to cytotoxic screening against HepG2 and THLE-2 cells, Compounds 10, 12e and 13a have a remarkable cytotoxic activity with IC50 values (10.7-13.9 µM). Compound 7 was found to be more cytotoxic by showing the lowest IC50 value of 7.26 compared to 5-FU (IC50 = 6.98 µM). It inhibited cell growth by 76.76%. Additionally, it significantly stimulated apoptotic liver cancer cell death with 49.78-fold (22.90% compared to 0.46% for the control) arresting cell cycle Pre-G1 with 35.16% of a cell population, compared to 1.57% for the control. Moreover, it validated the intrinsic apoptosis through upregulation of P53, and other related genes, with inhibition of anti-apoptotic genes through PIM-1 inhibition.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; In vivo; Liver cancer; Pyridines; RT-PCR

Year:  2021        PMID: 33839579     DOI: 10.1016/j.bioorg.2021.104877

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  4 in total

1.  Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies.

Authors:  Mohamed M Khalifa; Ahmed A Al-Karmalawy; Eslam B Elkaeed; Mohamed S Nafie; Mohamed A Tantawy; Ibrahim H Eissa; Hazem A Mahdy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

2.  Synthesis of Novel Phthalazinedione-Based Derivatives with Promising Cytotoxic, Anti-bacterial, and Molecular Docking Studies as VEGFR2 Inhibitors.

Authors:  Samir M El Rayes; Gaber El Enany; Ibrahim A I Ali; Wessam Ibrahim; Mohamed S Nafie
Journal:  ACS Omega       Date:  2022-06-27

3.  Silver Nanoparticles Formulation of Flower Head's Polyphenols of Cynara scolymus L.: A Promising Candidate against Prostate (PC-3) Cancer Cell Line through Apoptosis Activation.

Authors:  Amgad I M Khedr; Marwa S Goda; Abdelaziz F S Farrag; Ali M Nasr; Shady A Swidan; Mohamed S Nafie; Maged S Abdel-Kader; Jihan M Badr; Reda F A Abdelhameed
Journal:  Molecules       Date:  2022-09-24       Impact factor: 4.927

4.  In Vitro and In Vivo Studies of Anti-Lung Cancer Activity of Artemesia judaica L. Crude Extract Combined with LC-MS/MS Metabolic Profiling, Docking Simulation and HPLC-DAD Quantification.

Authors:  Marwa S Goda; Mohamed S Nafie; Basma M Awad; Maged S Abdel-Kader; Amany K Ibrahim; Jihan M Badr; Enas E Eltamany
Journal:  Antioxidants (Basel)       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.